NASDAQ:NLNK - NewLink Genetics Corporation
$1.55
 $0.07
+4.73%
2:00PM EDT
2019-02-15
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  NLNK     avg for
industry  
  avg for
sector  
42 stocks weight:  19. 79   0. 00   0. 00  
42 stocks rank:  3. 66 K 1. 86 K 1. 09 K
# analyst opinions:  3. 00   14. 92   14. 43  
mean recommendation:  3. 30   1. 91   1. 93  

quick ratio:  12. 85   5. 37   1. 81  
current ratio:  13. 33   5. 69   2. 19  

target price low:  1. 00   88. 97   117. 82  
target price avg:  1. 59   115. 19   141. 96  
target price high:  3. 33   143. 40   163. 16  
1-yr high:  8. 21   124. 30   142. 77  
last close:  1. 48   101. 85   127. 84  
50-day avg:  1. 56   98. 27   122. 46  
200-day avg:  3. 02   99. 72   122. 70  
1-yr low:  1. 33   78. 19   100. 16  
volume:  329. 47 K 2. 38 M 4. 64 M
50-day avg volume:  337. 32 K 3. 31 M 4. 94 M
200-day avg volume:  475. 13 K 3. 23 M 4. 28 M

1-day return:  0. 68 % 0. 22 % 0. 48 %
this week return:  -0. 67 % 1. 77 % 2. 01 %
12-wk return:  -23. 71 % 6. 56 % 3. 33 %
52-wk return:  -77. 02 % -2. 23 % 14. 35 %

enterprise value (EV):  -66. 46 M 55. 17 B 104. 51 B
market cap:  55. 09 M 49. 01 B 96. 46 B
EBITDA:  -63. 00 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  1. 05   -91. 79   2. 29  
enterprise/revenue (EV/R):  -2. 97   29. 84   23. 39  
total revenue:  22. 37 M 11. 28 B 40. 22 B
total debt:  133. 00 K 13. 73 B 16. 57 B
debt/equity:  0. 11   258. 01   110. 73  
net income (common):  -56. 71 M 2. 37 B 3. 58 B

shares outstanding:  37. 22 M 607. 99 M 1. 22 B
shares:  26. 21 M 605. 53 M 1. 15 B
shares short:  1. 33 M 11. 62 M 12. 55 M
shares short prior month:  1. 33 M 11. 95 M 13. 44 M
short ratio:  3. 38   4. 82   3. 10  
short % of float:  4. 62 % 6. 19 % 2. 82 %
total cash/share:  3. 28   12. 02   11. 46  
total cash:  122. 06 M 7. 41 B 7. 37 B
free cash flow:  -37. 13 M 95. 99 M 2. 04 B
operating cash flow:  -53. 83 M 164. 74 M 3. 04 B

book value:  3. 28   14. 43   28. 26  
price/book:  0. 45   -1. 57   -2. 97  
gross profits:  -40. 55 M 8. 28 B 18. 09 B
operating margins:  -287. 18 % -458. 01 % -642. 83 %
EBITDA margins:  -281. 62 % 13. 81 % 22. 47 %
profit margins:  -253. 52 % 6. 57 % 9. 92 %
gross margins:  -154. 51 % 49. 33 % 54. 53 %

1-yr max volatility:  -42. 62 % --- ---
1-yr mean volatility:  -0. 48 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 53   3. 03   4. 09  
forward EPS:  -1. 01   4. 33   6. 99  
P/E:  -0. 97   6. 11   26. 91  
forward P/E:  -1. 48   8. 38   10. 48  
PE/G:  0. 01   0. 37   5. 61  
growth:  -97. 80 % 683. 72 % 104. 79 %
earnings high:  -0. 30   1. 27   1. 66  
earnings avg:  -0. 34   1. 01   1. 53  
earnings low:  -0. 43   0. 76   1. 40  
revenue high:  380. 00 K 2. 86 B 11. 19 B
revenue avg:  140. 00 K 2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -28. 78 % -3. 27 % 3. 81 %
return on equity:  -49. 60 % 107. 48 % 27. 82 %
revenue growth:  -97. 80 % 648. 36 % 97. 70 %
revenue/share:  0. 60   14. 68   59. 83  

beta (1yr vs S&P500):  1. 42   1. 21   0. 93  
sharpe (1yr):  -1. 64   0. 06   0. 98  

held % insiders:  29. 44 % 6. 46 % 3. 21 %
held % institutions:  36. 77 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : NLNK
.        + 0 =             0 :: INITIAL WEIGHT
.  + 415.645 =       415.645 :: inverse volume-to-price addition
.  + 307.904 =       723.549 :: spline projection addition
.  - 162.556 =       560.993 :: poor performance penalty
.    x 0.521 =       292.502 :: one-year gains+dividend factor
.    x 2.811 =       822.271 :: 13 weeks' performance factor
.    x 1.492 =      1227.231 :: industry recommendation factor
.    x 0.997 =      1223.699 :: return on assets factor
.    x 0.995 =      1217.629 :: return on equity factor
.     x 0.99 =      1205.721 :: revenue growth factor
.    x 2.342 =      2823.304 :: current ratio factor
.    x 1.041 =      2940.057 :: quick ratio factor
.    x 1.138 =      3346.836 :: short ratio factor
.    x 2.005 =       6708.76 :: price-to-book factor
.      x 1.0 =      6710.177 :: debt-to-equity factor
.    x 5.506 =     36948.318 :: EBITDA multiple factor
.    x 2.171 =     80224.565 :: P/E weight
.    x 2.209 =    177212.785 :: PE/G factor
.    x 1.677 =    297251.412 :: beta factor
.    x 0.371 =    110379.146 :: sharpe factor
.    x 0.943 =    104093.111 :: target low factor
.    x 1.092 =    113618.957 :: target mean factor
.    x 1.112 =    126321.942 :: target high factor
.    x 1.066 =     134610.28 :: industry 12-weeks return
.    x 0.907 =    122144.795 :: "drift" penalty 1 days ago
.    x 0.998 =    121906.201 :: overall "drift" factor
.    x 0.998 =    121680.288 :: largest single-day jump factor
.    x 0.064 =      7750.337 :: low price factor
.      x 1.0 =      7750.857 :: factor hist industry gain for week 06
.   cubeRoot =         19.79 :: reduced for readability
.                      19.79 :: FINAL WEIGHT for NASDAQ:NLNK


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org